Charlotte Wernberg has been a medical doctor since 2014, when she graduated from medical school at the University of Southern Denmark and is currently a fellow at the University Hospital of Southern Denmark Esbjerg’s Department of Gastroenterology and Hepatology. Dr Wernberg enrolled as an ATLAS Ph.D. student in 2019 and successfully defended her Ph.D. thesis on biomarkers and cognitive impact of metabolically associated steatotic liver disease (MASLD) in April 2023. During her Ph.D. studies, Dr. Wernberg and the ATLAS team validated a soluble form of the protein triggering receptor expressed in myeloid cells 2 (TREM2) as a marker of metabolically associated steatohepatitis (MASH), and this important translational work was published in Hepatology in 2023 and gained widespread recognition.
Dr Wernberg has since 2023 continued her scientific career in a postdoc position in ATLAS 2.0 alongside her clinical training in Esbjerg. Her main role is to co-manage the PROMETHEUS study and, as such, oversee patient recruitment, data management, and supervision. The focus of Dr Wernberg’s postdoc will be post-bariatric surgery follow-up of participants in the PROMETHEUS study, focusing on the dynamics of biomarkers and cognition and a new sub study examining the impact of MASLD screening in people with type 2 diabetes.Charlotte W. Wernberg
Postdoc, MD
Department of Regional Health Research, University Hospital of Southern Denmark, Esbjerg
| Email: | Charlotte.Wilhelmina.Wernberg@rsyd.dk |
| Webpage: | Twitter/X @CharlotteWERN |
